Will Indian pharma withstand the Trump administration?

Investors are closely monitoring the performance of Indian pharma companies in the March 2025 quarter and their ability to grow US sales, at a time when the Trump administration has heavily cracked down on the sector. Investors could adopt a wait-and-watch attitude for pharma stocks and consider buying if there is a significant correction in valuations of pharma stocks.